Replies to post #6377 on Pluristem Therapeutics Inc (PSTI)

[Scott999]

Wish I could find what type of cost a treatment for entolimod costs. They do use third party manufacturing, and who knows if they would be able to meet an order of significance in a timely manner. At least with our own manufacturing ability, we can control that. A possible advantage over others.

[Scott999]

One in three's not that bad is it? I can only imagine if we don't get it. Only other thing that could get us moving higher in any significant way would be a partnership. And by the looks of things, that seems like a much less likely thing of happening.

Don't think any preclinical data from Fukishima or NYBC will move us. Possibly some great results from IC trial, but again, don't think it would move it too much. And that's not until early next year so they say. Ongoing open label trial was supposed to have interim data in the first half, but that got missed. Who knows what's happenimg with that.